title: Phase I-II study of aclarubicin for treatment of acute myeloid leukaemia.
authors.forename: D
authors.initials: D
authors.lastname: Machover
authors.forename: J
authors.initials: J
authors.lastname: Gastiaburu
authors.forename: M
authors.initials: M
authors.lastname: Delgado
authors.forename: E
authors.initials: E
authors.lastname: Goldschmidt
authors.forename: R
authors.initials: R
authors.lastname: Hulhoven
authors.forename: M
authors.initials: M
authors.lastname: Benavides
authors.forename: J P
authors.initials: JP
authors.lastname: Lotz
authors.forename: J L
authors.initials: JL
authors.lastname: Misset
authors.forename: F
authors.initials: F
authors.lastname: de Vassal
authors.forename: H
authors.initials: H
authors.lastname: Tapiero
mesh_terms: D015250:Aclarubicin; D000293:Adolescent; D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009279:Naphthacenes / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000903:Antibiotics, Antineoplastic; D009279:Naphthacenes; D015250:Aclarubicin